ClinicalTrials.gg

Program

berobenatide

Also written as “Berobenatide”, “PF-08653944” and “MET097”.

In Pfizer's pipeline, GLP-1 receptor agonist. Its studies are mostly in Obesity · Urinary Incontinence, Stress · Sleep Apnea, Obstructive · Sleep Apnea Syndromes · Diabetes Mellitus, Type 2, led by Pfizer.

Furthest: phase 3, since Dec 29, 202523 company-led studies, 17 open or runningNext primary completion: Jan 27, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Pfizer2317 open or runningphase 3since Dec 29, 2025Nov 27, 2024Jan 27, 2027phase 1 · NCT07508241
  • Named in Pfizer’s own pipeline as berobenatide PF-08653944, phase 3, as of Nov 3, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 2 studies since Nov 27, 2024.

  1. Mar 13, 2025Phase 2 study in Diabetes Mellitus, Type 2NCT06897202 · 133 enrolled · United States
  2. Apr 3, 2025Phase 2 study in ObesityNCT06924320 · 201 enrolled · United States
  3. May 6, 2025Phase 2 study in ObesityNCT06973720 · 268 enrolled · United States
  4. Dec 29, 2025Phase 3 study in ObesityPhase 3 reachedNCT07311850 · 3,578 enrolled · United States, Bulgaria, Canada and more
  5. Feb 3, 2026Phase 1 study in OverweightNCT07400679 · 48 enrolled · United States
  6. Feb 3, 2026Phase 3 study in ObesityNCT07400653 · 1,078 enrolled · United States, Argentina, Bulgaria and more
  7. Mar 27, 2026Phase 1 study in ObesityNCT07508241 · 22 enrolled · United States
  8. Apr 2, 2026Phase 1 study in HealthyNCT07519135 · 26 planned · United States
  9. May 12, 2026Phase 3 study in ObesityNCT07595549 · 954 planned · United States, Brazil, Canada and more
  10. Aug 25, 20263 phase 3 studies in ObesityNCT07792954, NCT07794774, NCT07794761
  11. Sep 11, 20263 phase 3 studiesNCT07823608, NCT07845500, NCT07874633
  12. Sep 22, 2026Phase 1 study in OverweightNCT07845513 · 11 enrolled · China
  13. Oct 9, 20264 phase 3 studiesNCT07881757, NCT07919678, NCT07915609 and 1 more
  14. Oct 9, 2026Phase 1 study in OverweightNCT07876531 · 144 planned · United States

Ahead

  1. Jan 27, 2027Primary completion: phase 1 study in ObesityNCT07508241
  2. Feb 21, 2027Primary completion: phase 1 study in OverweightNCT07845513
  3. Apr 6, 2027Primary completion: phase 1 study in OverweightNCT07876531
  4. Jul 9, 2027Primary completion: phase 1 study in HealthyNCT07519135

TargetBeta

“GLP-1 receptor agonist”the company's pipeline, read by Claude · source

Other programs on GLP1R

ProgramCompanyFurthest phaseStudies
SemaglutideruleNovo Nordiskphase 4170
LiraglutideruleNovo Nordiskphase 4116
TirzepatideruleEli Lillyphase 472
dulaglutideruleEli Lillyphase 447
orforglipronruleEli Lillyphase 350
survodutideBoehringer Ingelheimphase 335
zenagamtideNovo Nordiskphase 335
retatrutideruleEli Lillyphase 333
mazdutideruleInnovent Biologicsphase 327
bofanglutideruleGan & Lee Pharmaceuticalsphase 325
SafiglipronJiangsu HengRui Medicinephase 319
efpeglenatideruleHanmi Pharmaceuticalphase 313

Studies

All 23 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07932925Urinary Incontinence, Stress3Not yet recruitingOct 13, 2028900
NCT07919678Obesity · United States, Canada3RecruitingAug 22, 2028656
NCT07915609Obesity · United States3RecruitingAug 21, 2028756
NCT07881757Apnea · United States3RecruitingJun 1, 2028258
NCT07876531Overweight · United States1RecruitingApr 6, 2027144
NCT07874633Obesity · China3RecruitingJun 6, 2028432
NCT07845513Overweight · China1Active, not recruitingFeb 21, 202711
NCT07845500Obesity · United States, Australia3RecruitingFeb 16, 2028660
NCT07823608Apnea · United States3RecruitingApr 30, 2028258
NCT07794774Obesity · Japan3RecruitingFeb 21, 2029197
NCT07794761Obesity · Japan3RecruitingMar 14, 2029180
NCT07792954Obesity · China3RecruitingMar 14, 2028300
NCT07595549Obesity · United States, Brazil, Canada and more3RecruitingMay 4, 2028954
NCT07519135Healthy · United States1RecruitingJul 9, 202726
NCT07508241Obesity · United States1Active, not recruitingJan 27, 202722
NCT07400679Overweight · United States1CompletedJul 2, 202648
NCT07400653Obesity · United States, Argentina, Bulgaria and more3Active, not recruitingOct 12, 20271,078
NCT07311850Obesity · United States, Bulgaria, Canada and more3Active, not recruitingSep 21, 20273,578
NCT06973720Obesity · United States2CompletedDec 16, 2025268
NCT06924320Obesity · United States2CompletedSep 29, 2026201
NCT06897202Diabetes Mellitus, Type 2 · United States2CompletedDec 29, 2025133
NCT06857617Obesity · United States2CompletedJan 3, 2025120
NCT06712836Obesity · United States2CompletedJul 3, 2025239

How it is read

Names in the registry

  • “Berobenatide”, 11 entries
  • “PF-08653944”, 6 entries
  • “MET097”, 4 entries
  • “MET097 Injection”, 1 entry
  • “(Part C) MET097”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.